The biotech's candidate may treat a great number of illnesses that have one thing in common.

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

The U.S. FDA has begun piloting real-time clinical trial tracking in two cancer studies to speed up safety and efficacy monitoring. The move comes as CRISPR Therapeutics attracts investor attention ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech company, achieved a major milestone when it earned approval for the ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current ...

Non-model crop species represent a vast and diverse component of global agriculture, forestry, and horticulture, yet they are routinely underrepresented in ...

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a CRISPR genome editing technique that enables comparative analysis of the ...

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy ...